Interesting theory about H3 receptors ; if POIS is an allergy, it's definitely involves H3
How do we confirm that ? I've just read there is no anti H3 commercialized in my country..what about the vertigo drug ? Better than nothing ?
It might be but you'd have to take it under medical supervision. It agonises h1 receptors. Most anti-histamines are h1 inverse agonists so I'd be worried that taking an agonist before an O would make POIS symptoms worse. A possibility is taking betahistine after a h1 antagonist but that sounds risky also.
Other possibilities are mast cell stabilisers. These may reduce the overall levels of histamine and are used to treat some high histamine conditions. This could be a safer option for the moment.
I'm taking methionine to reduce histamine. It's not perfect but I sure feel a lot better. Oddly methionine and D-Ribose seems to work a bit better for me than SAMe. SAMe is good though but it kicks in fast and I feel my allergies returning in a few hours. I've also noticed that the now b vitamins I take has TMG / Betaine which is also used in methylation reactions.
Until h3 inverse agonists with either no or inverse agonistic effects on h1 and h2 are available then there's no
"silver bullet" and this assumes that this theory is correct. I have a hunch that h3 inverse agonists will prove to be successful ADHD medications as I've heard some people say SAMe and methionine helped with their ADHD, implying there may be a common histamine connection to our problem and some sufferers of attention disorders. Pitolisant (another H3 inverse agonist) has shown some efficacy in studies to treat schizophrenia. Similarly with
http://en.wikipedia.org/wiki/ABT-239this class of drugs appears to have a nootropic affect, stimulating memory, learning, concentration and increasing intelligence.
This is an emerging area in neuroscience research. This overview paper is as recent as 2004
http://learnmem.cshlp.org/content/11/1/1.fullRemember that drugs can have a very long gestation period. Pharmaceutical companies don't rush them out on the market.
Clinical trials are showing that dosages are very important. In our brains, the h3 receptor triggered reduction of neurotransmitter production is being done by the body for safety reasons. Accepting that some people (POIS sufferers perhaps) could have a malfunction, most people would not want their h3 receptors antagonised on a permeant basis. It could prove overstimulating, affect cardiac rhythms etc. It may be safer than amphetamines but these will still be powerful drugs.
Anyway, it's a research area for NORD to consider.